ハーバ・サークンダの抗腫瘍活性成分であるβ-シトステロールは,TBX20のアップレギュレーションによって大腸がんの進行を抑制する.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
PubMedで要約を見る
まとめ
この要約は機械生成です。この研究は,Herba Sarcandraeの化合物であるβ-シトステロールが結腸直腸がん (CRC) の治療を強化することを示しています. 化学療法薬に対する感受性を高め,TBX20タンパク質を安定させ,腫瘍の成長を抑制します.
科学分野
- 腫瘍学
- 薬理学について
- 分子生物学
背景
- 大腸がん (CRC) は,消化管の悪性腫瘍である.
- ハーバ・サーカンドレイ (HS) は抗がん性があると報告されています.
- 化学療法に対する耐性は,CRCの治療における課題です.
研究 の 目的
- β-シトステロールが5-フッ素ウラシル (5-FU) とオクサリプラチンに対するCRC感受性に対する影響を調査する.
- CRC 細胞における TBX20 タンパク質の安定性に対する β-シトステロールの影響を調べる.
- HSから派生したβ-シトステロールの抗癌メカニズムを解明する.
主な方法
- HS活性成分とCRCにおける標的のバイオ情報分析
- TBX20と相互作用する可能性のある化合物 (エピメディンC,ルーチン,β-シトステロール) のスクリーニングと検証
- CRC細胞増殖とアポトーシスに関する in vitro 測定と in vivo 異種移植モデル
主要な成果
- β-シトステロールはCRC細胞増殖を抑制し,アポトーシスを誘発した.
- β-シトステロールは,5-FUとオクサリプラチンに対するCRCの感受性を高めました.
- β-シトステロール治療は,腫瘍の成長を抑制し,TBX20を上昇させ,分解を減らし,安定させました.
結論
- β-シトステロールはHSの活性抗腫瘍成分です.
- β-シトステロールは,TBX20の安定化によって増殖を抑制し,アポトーシスを促進することによってCRCと戦う.
- β-シトステロールは化学療法の有効性を高め,CRCの潜在的な治療戦略を提供します.
関連する概念動画
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...